ScreenerHero

KALVKalVista Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · kalvista.com
27.00USD0.00%Mkt Cap: 1.44B $P/E: —

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.44B $
Enterprise Value1.44B $
Revenue (TTM)114.48M $
Gross Profit58.47M $
Net Income (TTM)-135.94M $
Revenue/Share2.110 USD
Last Price27.00 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees275
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS4834971032
Valuation
P/E (Trailing)—
P/E (Forward)17.48
PEG—
EV/EBITDA-10.38
EV/Revenue12.55
P/S12.56
P/B—
EPS (TTM)-3.94
EPS (Forward)1.71
52W Range
9.830100% of range27.00
52W High27.00 USD
52W Low9.830 USD
Profitability
Gross Margin51.07%
Oper. Margin-57.37%
EBITDA Margin-120.94%
Profit Margin-118.74%
ROE—
ROA—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-89.32M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-718.02K $
Net Debt/EBITDA0.01
Balance Sheet
Debt/Equity—
Current Ratio5.17
Quick Ratio4.97
Book Value/Sh-0.3840 USD
Cash/Share5.354 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:14
Split DateNov 22, 2016
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.00 USD
Upside (mean)+0.0%
Target Range27.00 USD – 27.00 USD
# Analysts3
Ownership
Shares Out.53.24M
Float38.18M
Insiders1.72%
Institutions136.88%
Short Interest
Short Ratio0.9d
Short % Float14.37%
Short % Out.12.85%
Shares Short6.84M
Short (prev mo.)15.16M
Technical
SMA 5024.43 (+10.5%)
SMA 20017.09 (+58.0%)
Beta-0.11
S&P 52W Chg18.16%
Avg Vol (30d)3.38M
Avg Vol (10d)2.09M
Technical Indicators
RSI (14)76.3
MACD0.7269
MACD Signal0.9492
MACD Hist.-0.2223
BB Upper27.06 USD
BB Middle26.86 USD
BB Lower26.66 USD
BB Width1.49%
ATR (14)0.2178 USD
Vol Ratio (20d)0.00x